期刊文献+

瑞舒伐他汀治疗不稳定型心绞痛疗效及对血脂、血浆金属蛋白酶的影响 被引量:11

The Effect of Rosuvastatin Tablets on the Plasma Levels of Lipid and Etalloprotease in the Treatment of Patients with Unstable Anginapectoris
原文传递
导出
摘要 目的:探讨瑞舒伐他汀对不稳定型心绞痛患者血脂和血浆金属蛋白酶(MMPs)的影响。方法:68例不稳定型心绞痛患者随机分为观察组和对照组各34例。对照组予抗凝、扩血管、降脂和改善心肌微循环等综合性对症支持治疗;观察组在此基础上加用瑞舒伐他汀片10 mg,po qd,连用6个月。观察两组血脂(TC、TG、LDL-C、HDL-C)和血浆MMP-2和MMP-8水平变化。比较两组临床总有效率。结果:观察组患者TC、TG和LDL-C水平均较前明显下降,HDL-C水平较前明显上升(P<0.05),对照组血脂各指标治疗前后无明显变化(P>0.05);治疗后两组血浆MMP-2和MMP-8水平较治疗前明显下降(P<0.05或0.01),且观察组下降幅度更显著(P<0.05)。观察组临床总有效率明显优于对照组(P<0.05),治疗期间两组均未出现明显不良反应。结论:阿瑞舒伐他汀治疗不稳定型心绞痛具有较好的疗效,安全性较好,能明显降低血脂和血浆MMP-2和MMP-8水平,有利于动脉粥样硬化斑块的稳定,具有良好的心血管保护作用。 Objective : To explore the effect of rosuvastatin tablets on the plasma levels of lipid and metalloprotease in the treatment of patients with unstable anginapectoris (UAP). Methods :68 patients with UAP were randomly divided into the observation group (34 cases) and controlled group (34 cases). All the patients got comprehensive traditional supportive treatments as anti-freezing, vessel-dilation, lipid-reduction, and myocardium-microcirculation-improving. The patients in the observation group got an extra treatment by taking rosuvastatin tablets orally 10mg, once a day for 6 months. The levels of TC,TG,LDL-C,HDL-C, MMP-2 and MMP-8 were observed. And the total effective rates of the two groups were analyzed. Results:The levels of TC ,TG and LDL-C of the observation group reduced more significantly after the treatment than before it, but the level of HDL-C increased( P 〈0.05 ). The indexes of the controlled group showed no significant change after the treatment(P 〉 0.05 ). The plasma levels of MMP-2 and MMP-8 of the two groups reduced more than those before the treatment ( P 〈 0.05 or P 〈 0.01 ). And the change in the observation group was more obvious than that in the controlled group(P 〈 0.05 ). The total clinic effective rate of the observation group was significantly higher than that of the controlled group ( P 〈 0.05 ), but no side effect was found in the two groups during the treatment. Conclusion: The treatment of patients with UAP with rosuvastatin could reduce the level of lipid and MMP-2 and MMP-8, play a good role in the stability of atheromatous plaque, show a good protection for cardiovascular, and therefore show effective and safe results.
作者 张捷军 凌杰
出处 《药物流行病学杂志》 CAS 2013年第4期166-168,共3页 Chinese Journal of Pharmacoepidemiology
关键词 不稳定型心绞痛 瑞舒伐他汀 血脂 金属蛋白酶 疗效 Unstableanginapectoris Rosuvastatin Blood lipid Metalloprotease Curative effect
  • 相关文献

参考文献8

二级参考文献29

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 3张清华,田莉,蒋知新,陈东.基质金属蛋白酶-9和妊娠相关血浆蛋白酶A及hs-CRP与急性冠脉综合征的相关性[J].心血管康复医学杂志,2007,16(2):142-144. 被引量:5
  • 4中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 5Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. Lancet,2002,360 : 7-22.
  • 6Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in ld randomised trials of statins. Lancet,2005, 366 : 1267-1278.
  • 7Smith SC Jr,Allen J,Blair SN ,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease : 2006 update. Circulat on, 2006,113:2363-2372.
  • 8Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III:a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prey Rehabil,2009,16 : 121-137.
  • 9Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease ( PROSPER ) : a randomised controlled trial. Lancet,2002,360 : 1623-1630.
  • 10Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med,2006,355: 549-559.

共引文献2772

同被引文献75

引证文献11

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部